AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28321826 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Kidilact® sachet containing Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium infantis, Bifidobacterium breve, and Streptococcus thermophiles)
Number of subjects: 0
Study 28321826 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo sachets)
Number of subjects: 0
Study 28321826 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Kidilact® sachet)
Number of subjects: 0
Study 25809828 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 treatment
Number of subjects: 31
Study 23328275 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg QD for 5 days
Number of subjects: 16
Study 23328275 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg QD and Linagliptin 5 mg QD for 7 days
Number of subjects: 16
Study 23328275 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg QD for 7 days
Number of subjects: 16
Study 22333547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration-positive group (n = 38)
Number of subjects: 132
Study 22333547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration-negative group (n = 28)
Number of subjects: 132
Study 22333547 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 66)
Number of subjects: 132
Study 19448187 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 hours of computerized auditory training
Number of subjects: 55
Study 19448187 — intervention group
Group type: COMPARATOR
Intervention: Control condition using computer games
Number of subjects: 55
Study 17277011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive district-level training workshops and supportive supervision visits
Number of subjects: 72
Study 17277011 — intervention group
Group type: COMPARATOR
Intervention: Cascade training package
Number of subjects: 72
Study 15474134 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone)
Number of subjects: 10008
Study 15474134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10008
Study 11840382 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancy (group 2)
Number of subjects: 85
Study 11840382 — intervention group
Group type: COMPARATOR
Intervention: Preeclampsia (group 3)
Number of subjects: 85
Study 9541433 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 12
Study 9541433 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol
Number of subjects: 12
Study 9541433 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 12
Study 8021064 — intervention group
Group type: EXPERIMENTAL
Intervention: RM cup
Number of subjects: 120
Study 8021064 — intervention group
Group type: COMPARATOR
Intervention: PCA cup
Number of subjects: 120
Study 2704497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (24 mg of betamethasone)
Number of subjects: 165
Study 2704497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (2 g intravenous every 6 hours)
Number of subjects: 165
Study 2704497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both corticosteroids and ampicillin
Number of subjects: 165
Study 2704497 — intervention group
Group type: COMPARATOR
Intervention: Neither ampicillin nor corticosteroids (Control Group I)
Number of subjects: 165
Study 894647 — intervention group
Group type: EXPERIMENTAL
Intervention: Monistat cream (miconazole nitrate 2%) for 7 days
Number of subjects: 139
Study 894647 — intervention group
Group type: EXPERIMENTAL
Intervention: Monistat cream (miconazole nitrate 2%) for 10 days
Number of subjects: 139
Study 894647 — intervention group
Group type: COMPARATOR
Intervention: Monistat cream (miconazole nitrate 2%) for 14 days
Number of subjects: 139
Study 31533676 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session family-and group-based cognitive-behavioral intervention to prevent youth depression
Number of subjects: 40
Study 26187939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol (24 hours to 12 hours in 1 day)
Number of subjects: 63
Study 26187939 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (2 days to transition)
Number of subjects: 63
Study 26187939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol
Number of subjects: 63
Study 26187939 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 63
Study 1426215 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms b.i.d.
Number of subjects: 667
Study 1426215 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol, 200 micrograms q.i.d.
Number of subjects: 667
Study 22902198 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo (GEXP)
Number of subjects: 8
Study 22902198 — intervention group
Group type: COMPARATOR
Intervention: No treatment (baseline period)
Number of subjects: 8
Study 22902198 — intervention group
Group type: COMPARATOR
Intervention: No treatment (6-month follow-up)
Number of subjects: 8
Study 20416236 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care with parallel father testing (n=677)
Number of subjects: 1441
Study 20416236 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care with sequential father testing (n=590)
Number of subjects: 1441
Study 20416236 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=441)
Number of subjects: 1441
Study 20416236 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=90)
Number of subjects: 1441
Study 20416236 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1441
Study 20416236 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care with parallel testing
Number of subjects: 1441
Study 20416236 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care with sequential testing
Number of subjects: 1441
Study 18983791 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (20 g/d)
Number of subjects: 80
Study 18983791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15659079 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg, b.i.d.)
Number of subjects: 15
Study 15659079 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (80 mg, b.i.d.)
Number of subjects: 15
Study 12641684 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 4% in 2:1 ratio of air:O2 mixture
Number of subjects: 50
Study 12641684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in 2:1 ratio of air:O2 mixture
Number of subjects: 50
Study 12641684 — intervention group
Group type: COMPARATOR
Intervention: Control ECG recording before induction of anaesthesia
Number of subjects: 50
Study 10321537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.3 mg atropine
Number of subjects: 6
Study 10321537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular administration of 0.3 mg atropine
Number of subjects: 6
Study 10321537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and ocular administration of 0.3 mg atropine
Number of subjects: 6
Study 8889087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Behavioural Memory Test
Number of subjects: 70
Study 8889087 — intervention group
Group type: EXPERIMENTAL
Intervention: EMQ20 questionnaire
Number of subjects: 70
Study 8889087 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory aids usage
Number of subjects: 70
Study 1753598 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN + captopril
Number of subjects: 14
Study 1753598 — intervention group
Group type: COMPARATOR
Intervention: ISDN
Number of subjects: 14
Study 1753598 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14
Study 6347689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (low-osmolar contrast media)
Number of subjects: 47
Study 6347689 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate (high-osmolar contrast media)
Number of subjects: 47
Study 30946150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days a week (3W) Atripla
Number of subjects: 61
Study 30946150 — intervention group
Group type: COMPARATOR
Intervention: Once-daily Atripla
Number of subjects: 61
Study 29855315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $5000 for the first year of localized breast cancer treatment
Number of subjects: 460
Study 29855315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $15,000 for the first year of localized breast cancer treatment
Number of subjects: 460
Study 29855315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $20,000 for the first year of localized breast cancer treatment
Number of subjects: 460
Study 26858335 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 40,000 IU subcutaneously once a week
Number of subjects: 2098
Study 26858335 — intervention group
Group type: COMPARATOR
Intervention: Best standard of care
Number of subjects: 2098
Study 23907785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR) neuromodulation therapy, delivered 4-6 hours/day for more than 12 weeks
Number of subjects: 0
Study 23907785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR) neuromodulation therapy
Number of subjects: 0
Study 21542113 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using paclitaxel-eluting stents
Number of subjects: 1800
Study 21542113 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study 19448233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 50
Study 19448233 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation infraclavicular brachial plexus block
Number of subjects: 50
Study 17148942 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal dispersion with PVP‐I (2.2%)
Number of subjects: 0
Study 17148942 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal dispersion with PVP‐I (4.4%)
Number of subjects: 0
Study 17148942 — intervention group
Group type: COMPARATOR
Intervention: Liposomal dispersion with PVP‐I (0%)
Number of subjects: 0
Study 16943223 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing added to cervical screening
Number of subjects: 0
Study 15181065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 7
Study 15181065 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 7
Study 10808574 — intervention group
Group type: EXPERIMENTAL
Intervention: Grippol trivalent polymer-subunit influenza vaccine
Number of subjects: 0
Study 10808574 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8606276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate
Number of subjects: 390
Study 8606276 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 390
Study 8606276 — intervention group
Group type: COMPARATOR
Intervention: Prazosin and placebo therapy
Number of subjects: 390
Study 1484191 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine
Number of subjects: 0
Study 1484191 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine
Number of subjects: 0
Study 1484191 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 3912314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine, 50 mg three times a day for 6 weeks
Number of subjects: 66
Study 3912314 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone, 100 mg three times a day for one week followed by 50 mg three times a day for the remaining five weeks
Number of subjects: 66
Study 3912314 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone
Number of subjects: 66
Study 3912314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 66
Study 31116190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-on-1 (Fo1) group with 8 to 10 teeth prostheses
Number of subjects: 20
Study 31116190 — intervention group
Group type: COMPARATOR
Intervention: Fixed-on-2 (Fo2) group with 12 teeth prostheses
Number of subjects: 20
Study 31116190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 31116190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-on-1 (Fo1) group
Number of subjects: 20
Study 31116190 — intervention group
Group type: COMPARATOR
Intervention: Fixed-on-2 (Fo2) group
Number of subjects: 20
Study 28583143 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced SleepTrackTXT2 intervention involving text-message assessments and behavior change messages.
Number of subjects: 0
Study 28583143 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving text messages that only include assessments.
Number of subjects: 0
Study 28583143 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced SleepTrackTXT2 intervention.
Number of subjects: 0
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to RTI symptoms
Number of subjects: 230
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to GTI symptoms
Number of subjects: 230
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported exposure outside the workplace for RTI
Number of subjects: 230
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported exposure outside the workplace for GTI
Number of subjects: 230
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated RTI episodes without reported exposure
Number of subjects: 230
Study 25879224 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated GTI episodes without reported exposure
Number of subjects: 230
Study 23831866 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 10
Study 23831866 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 21402624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic IDA (n = 27)
Number of subjects: 161
Study 21402624 — intervention group
Group type: COMPARATOR
Intervention: Corrected IDA (n = 70)
Number of subjects: 161
Study 21402624 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic (n = 64)
Number of subjects: 161
Study 19490617 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after concurrent chemoradiotherapy
Number of subjects: 283
Study 17461372 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 434
Study 17461372 — intervention group
Group type: COMPARATOR
Intervention: Low social support
Number of subjects: 434
Study 15514412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extended treatment
Number of subjects: 160
Study 15514412 — intervention group
Group type: EXPERIMENTAL
Intervention: Active brief treatment
Number of subjects: 160
Study 15514412 — intervention group
Group type: COMPARATOR
Intervention: Placebo extended treatment
Number of subjects: 160
Study 15514412 — intervention group
Group type: COMPARATOR
Intervention: Placebo brief treatment
Number of subjects: 160
Study 11180305 — intervention group
Group type: EXPERIMENTAL
Intervention: Three methods of promoting secondary prevention of coronary heart disease
Number of subjects: 2142
Study 11180305 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2142
Study 9475021 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% solution
Number of subjects: 21
Study 9475021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7897085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 64
Study 7897085 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 64
Study 2955980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (200 micrograms)
Number of subjects: 16
Study 2955980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (200 micrograms) and inhaled ipratropium bromide (60 micrograms)
Number of subjects: 16
Study 31009400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced peripheral nerve evaluation (ePNE) using tined quadripolar electrode leads over 6 weeks
Number of subjects: 45
Study 28775677 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI training sessions (n = 55), 10 sessions lasting up to 40 min each, involving motor imagery of opening the affected hand.
Number of subjects: 74
Study 28775677 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19), hand exoskeleton-driven movements independent of brain activity.
Number of subjects: 74
Study 25788668 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulation (DS)
Number of subjects: 0
Study 25788668 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functions (EFs)
Number of subjects: 0
Study 25788668 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG theta waves
Number of subjects: 0
Study 25788668 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI connectivity analysis
Number of subjects: 0
Study 23846568 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of women not on ART)
Number of subjects: 1285
Study 21414053 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene covers
Number of subjects: 18
Study 21414053 — intervention group
Group type: COMPARATOR
Intervention: Carbomer drops
Number of subjects: 18
Study 19345771 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CIT) for 10 consecutive weekdays, 6 hours a day, with trainer-supervised, functionally based activities using massed practice.
Number of subjects: 10
Study 16989011 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin (2 g intravenous dose)
Number of subjects: 618
Study 16989011 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 618
Study 15320655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense basketball-simulated exercise
Number of subjects: 48
Study 15320655 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic men)
Number of subjects: 48
Study 14599634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation (brachytherapy)
Number of subjects: 0
Study 14599634 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 10768434 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 45
Study 10768434 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 45
Study 8617187 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled rice with high amylose content
Number of subjects: 12
Study 8617187 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled rice with low amylose content
Number of subjects: 12
Study 8617187 — intervention group
Group type: COMPARATOR
Intervention: Non-parboiled rice
Number of subjects: 12
Study 8617187 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 12
Study 1618212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (50 mg patch, 10 mg.24 h-1)
Number of subjects: 12
Study 1618212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h nitrate-free period
Number of subjects: 12
Study 1618212 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h nitrate-free period
Number of subjects: 12
Study 1618212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2931973 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper gluconate (10 mg/day)
Number of subjects: 7
Study 2931973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30380991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar shortening osteotomy with arthroscopic debridement
Number of subjects: 44
Study 30380991 — intervention group
Group type: COMPARATOR
Intervention: Ulnar shortening osteotomy alone
Number of subjects: 44
Study 30672180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint group (acupuncture at Zhaohai (KI 6), Taichong (LR 3), Lingdao (HT 4), Neiguan (PC 6), Shenmen (HT 7), Danzhong (CV 17), Baihui (GV 20), Fengchi (GB 20))
Number of subjects: 160
Study 30672180 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acupoint group (acupuncture at points 0.5 cun next to the acupoints)
Number of subjects: 160
Study 30672180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham-acupoint group (acupuncture at unrelated acupoints)
Number of subjects: 160
Study 30672180 — intervention group
Group type: COMPARATOR
Intervention: Blank group (no treatment)
Number of subjects: 160
Study 26725013 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based course design using concept mapping
Number of subjects: 0
Study 26725013 — intervention group
Group type: COMPARATOR
Intervention: Objective-based lectures
Number of subjects: 0
Study 25377444 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg orally every 12 hours for 24 weeks
Number of subjects: 107
Study 25377444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 23148287 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 265
Study 23148287 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir plus ritonavir (ATV/r)
Number of subjects: 265
Study 20393393 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Graded Activity (BGA) program
Number of subjects: 146
Study 20393393 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 146
Study 18615666 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g calcium
Number of subjects: 15
Study 18615666 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D(3)
Number of subjects: 15
Study 18615666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 g calcium and 2,000 IU vitamin D(3)
Number of subjects: 15
Study 18615666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16102292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal probiotics (n = 50)
Number of subjects: 117
Study 16102292 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 67)
Number of subjects: 117